NeoStem, Inc. To Buy Californian Peer For $124 Million+

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NeoStem (NBS) has agreed to acquire start-up California Stem Cell, which has developed Melapuldencel-T, an immune based-therapy designed to eliminate tumor cells that can cause disease recurrence. NeoStem will pay 5.33M shares - worth 34.1M based on the firm's closing price of $6.40 on Friday - as well as up to $90M in milestone and royalty payments in cash or shares. NeoStem is currently trading up 9.4% at $7 per share in premarket action.

Help employers find you! Check out all the jobs and post your resume.

Back to news